Based on reporting from CNBC Business, Vivani Medical is developing a small implant designed to deliver semaglutide, the active ingredient found in well-known obesity and diabetes medicines.
Semaglutide is the same drug used in Novo Nordisk’s obesity injection Wegovy and its diabetes treatment Ozempic. The headline idea in this new approach is continuity: a device-based delivery method could be positioned as a way for patients to better maintain weight loss over time, rather than relying only on injection routines.
For small- and mid-size business owners, the practical takeaway is that the competitive landscape for obesity and metabolic care continues to evolve. Drugmakers and medical device companies may increasingly collaborate, and new products can change demand patterns across healthcare supply chains, distribution channels, and patient services.
Even without details beyond the reporting, this kind of development signals that obesity treatment is still an active innovation frontier. That matters for any business with healthcare customers, partners, or employees who may be affected by shifting treatment experiences.
Source: CNBC Business
